Report Details:
15 Companies Covered
90 Pages
Helicobacter Pylori Test Market Market Highlights
The Helicobacter Pylori Test Market Size was estimated at 3234.48 USD Million in 2024. The Helicobacter Pylori Test industry is projected to grow from 3418.91 USD Million in 2025 to 5952.8 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period 2025 - 2035.
The need for personalized antibiotic therapies and technological developments in testing diagnostics fuels market growth, together with increasing rates of gastrointestinal disorders. Helicobacter pylori (H. pylori), a gram-negative stomach bacterium, causes peptic ulcers, duodenal ulcers, and gastric cancer, and is responsible for associated conditions, thereby increasing the global burden for which testing, especially in hospitals and clinics, is on the rise.
The expected accuracy of endoscopic testing for the diagnosis of H. pylori infection continues to keep this segment dominant in the market. At the same time, immunoassay-based technology remains the diagnostics segment leader due to its commercially viable sensitivity and cost. Furthermore, the development of non-invasive tests (breath tests, stool antigen tests) helps patients with compliance to testing and diagnosis.
The market continues to grow for awareness campaigns on early detection, along with the market-multiplying effect of the WHO for early detection.
MRFR recognizes the following companies as the key players in the Global Helicobacter Pylori Test Market: Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Meridian Bioscience Inc., CorisBioconcept SPRL, Cardinal Health, QIAGEN, Abbott Laboratories, and Biohit Oyj.
Segment Analysis
The Global Helicobacter Pylori Test Market has been segmented based on Test Type, Technology, and End User.
By Test Type:
The market is divided into Endoscopic and Non-Endoscopic tests. The Endoscopic segment held the largest share in 2024, owing to its superior accuracy and diagnostic reliability for detecting H. pylori infections.
By Technology:
Segments include Immunoassays, Molecular Diagnostics, and Point-of-Care Testing. The Immunoassays segment dominated the market, driven by the widespread use of enzyme immunoassays and serological tests for antibody detection.
By End User:
The market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Others. The Hospitals & Clinics segment led the market in 2024 due to high patient inflow, accessibility to medical professionals, and availability of advanced diagnostic infrastructure.
Regional Analysis
By Region, the Global Helicobacter Pylori Test Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global market in 2024, driven by a robust healthcare infrastructure, high awareness about early disease detection, and widespread adoption of advanced diagnostic technologies. The U.S. accounted for the largest market share due to increasing cases of peptic ulcers and strong reimbursement frameworks.
Europe held the second-largest share, supported by growing incidences of infectious diseases and expanding healthcare initiatives. Germany led the regional market, while the UK emerged as the fastest-growing sub-market.
Asia Pacific is projected to exhibit the fastest CAGR during the forecast period. Factors such as a growing patient base, improving healthcare access, and government-backed initiatives for infection control in China and India are contributing to this regional growth.
Key Findings of the Study
- Technological advancements in testing methodologies are enhancing the accuracy and efficiency of Helicobacter Pylori diagnostics.
- North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for Helicobacter Pylori testing.
- The Urea Breath Test continues to dominate the market, whereas the Stool Antigen Test is witnessing rapid growth due to its non-invasive nature.
- Rising incidence of Helicobacter Pylori infections and increased focus on gastrointestinal health are key drivers propelling market expansion.
Industry Developments
- May 2022: Biomerica Inc. received CE Mark approval for its hp+detect diagnostic test, enabling its commercialization across multiple countries for H. pylori detection.
- July 2023: Meridian Bioscience Inc. acquired Otsuka America Pharmaceutical’s BreathTek business for USD 20 million to expand its H. pylori diagnostic portfolio.
- April 2021: Otsuka launched the QuickNavi™-H. Pylori detection kit, providing results within 8 minutes using immunochromatography-based stool antigen testing.
Future Outlook
The Global Helicobacter Pylori Test Market is expected to grow consistently over the next ten years due to technological advancements, rising infection rates, and favorable regulations encouraging proactive detection.
Emerging opportunities include:
- Creating point-of-care testing innovations to enhance accessibility and speed regarding accurate diagnosis.
- Integration of AI predictive tools for advanced test precision and more efficient management of patients.
- New Partnerships between Health professionals and diagnostic firms for the H. pylori test are a regular part of health assessment.
- Market activity between now and 2035 indicates an increase in the rate of Early diagnosis and management of infections to avoid complications to the gastrointestinal tract.
